NCT05112666View on ClinicalTrials.gov

A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK)

CompletedOBSERVATIONAL
Enrollment

2,601

Participants

Timeline

Start Date

December 2, 2021

Primary Completion Date

August 26, 2022

Study Completion Date

August 26, 2022

Conditions
Treatment of Venous Thromboembolism in Cancer Patients
Interventions
DRUG

Rivaroxaban (Xarelto, BAY59-7939)

Retrospective cohort analysis using Clinical Practice Research Datalink (CPRD) GOLD and Aurum Hospital Episode Statistics (HES)-linked datasets in UK.

DRUG

other DOACs

Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.

DRUG

LMWH

Retrospective cohort analysis using CPRD GOLD and Aurum HES-linked datasets in UK.

Trial Locations (1)

Unknown

Many locations, Multiple Locations

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
collaborator

Janssen Research & Development, LLC

INDUSTRY

lead

Bayer

INDUSTRY

NCT05112666 - A Study to Gather Information About Rivaroxaban in Patients in the United Kingdom Who Have Cancer and Thrombosis (OSCAR-UK) | Biotech Hunter | Biotech Hunter